The molecular genetics of breast cancer and targeted therapy

Biologics: Targets and Therapy

Volumn 1, Issue 3, 2007, Pages 241-258

  Suter, Rachel ^a   Marcum, James A ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b BAYLOR UNIVERSITY   (United States)

Author keywords

Breast cancer; Oncogenes; Targeted therapy; Tumor suppressor genes

Indexed keywords

EID: 83255161994     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (260)

1. Adjei AA, Dy GK, Erlichman C, et al. 2003. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res, 9:115-23.
2. Akli S, Keyomarsi K. 2003. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther, 2(Suppl 1):S38-47.
3. Akli S, Keyomarsi K. 2004. Low-molecular-weight cyclin E: the miss- ing link between biology and clinical outcome. Breast Cancer Res, 6:188-91.
4. Alessandro R, Clair T, Liotta LA, et al. 2004. The cellular microenviron- ment. In: Abeloff MD, Armitage JO, Niederhuber JE, et al eds. Clinical oncology. 3rd ed. Philadelphia, PA: Elsevier Churchill Livingstone. p 47-58.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100:3983-8.
6. Altundag K, Ibrahim NK. 2006. Aromatase inhibitors in breast cancer. Oncologist, 11:553-62.
7. Antoniou AC, Easton DF. 2006. Models of genetic susceptibility to cancer. Oncogene, 25:5898-905.
8. Arnold A, Papanikolaou A. 2005. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol, 23:4215-24.
9. Baker SJ. 2007. PTEN enters the nuclear age. Cell, 128:25-8.
10. Bange J, Zwick E, Ullrich A. 2001. Molecular targets for breast cancer therapy and prevention. Nat Med, 7:548-52.
11. Baselga J, Perez EA, Pienkowski T, et al. 2006. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 11(Suppl 1):4-12.
12. Basso AD, Mirza A, Liu G, et al. 2005. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem, 280:31101-8.
13. Bazley LA, Gullick WJ. 2005. The epidermal growth factor receptor family. Endocr Relat Cancer, 12:S17-27.
14. Begg CB. 2002. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst, 94:1221-6.
15. Berglund P, Landberg G. 2006. Cyclin E overexpression reduces infiltrative growth in breast cancer: yet another link between proliferation control and tumor invasion. Cell Cycle, 5:606-9.
16. Berns EMJJ, Foekens JA, van Staveren IL, et al. 1995. Oncogene amplifica- tion and prognosis in breast cancer; relationship and systemic treatment. Gene, 159:11-8.
17. Bianco R, Ciardiello F, Tortora G. 2005. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets, 5:51-6.
18. Bièche I, Lidereau R. 2000. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog, 29:151-8.
19. Børresen-Dale AL. 2003. TP53 and breast cancer. Hum Mutat, 21:292-300.
20. Bosco EE, Wang Y, Xu H, et al. 2007. The retinoblastoma tumor suppres- sor modifies the therapeutic response of breast cancer. J Clin Invest, 117:218-28.
21. Bose S, Chandran S, Mirocha JM, et al. 2006. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol, 19:238-45.
22. Bossi G, Sacchi A. 2007. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck, 29:272-84.
23. Bouchet BP, de Fromentel CC, Puisieux A, et al. 2006. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol, 58:190-207.
24. Boveri T. 1914. Zur Frage der Entstehung maligner Tumoren. Jena: Fischer.
25. BRCA Trial. 2007. A randomized phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer. Accessed 9 August 2007. URL: http://www.geneticbreastcancertrial.usilu.net/Home.asp.
26. Braithwaite AW, Royds JA, Jackson P. 2005. The p53 story: layers of complexity. Carcinogenesis, 26:1161-9.
27. Brody JG, Rudel RA, Michels KB, et al. 2007. Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? Cancer, 109:2627-34.
28. Bryant HE, Schultz N, Thomas HD, et al. 2005. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434:913-17.
29. Burris HA III. 2004. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist, 9(Suppl 3):10-5.
30. Butt AJ, McNeil CM, Musgrove EA, et al. 2005. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer, 12:S47-59.
31. Bykov VJ, Zache N, Stridh H, et al. 2005. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene, 12:3484-91.
32. Caldon CE, Daly RJ, Sutherland RL, et al. 2006. Cell cycle control in breast cancer cells. J Cell Biochem, 97:261-74.
33. Carroll JS, Swarbrick A, Musgrove EA, et al. 2002. Mechanism of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of estrogens. Cancer Res, 62:3126-31.
34. Chan S, Johnson S, Scheulen M. 2002. First report: a phase II study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc Am Soc Clin Oncol, 21:44a.
35. Chan SK, Hill ME, Gullick WJ. 2006. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia, 11:3-11.
36. Chano T, Kontani K, Teramoto K, et al. 2002. Truncating mutations of RB1CC1 in human breast cancer. Nat Genet, 31:285-8.
37. Chau BN, Pan CW, Wang JYJ. 2006. Separation of anti-proliferation and anti-apoptotic functions of retinoblastoma protein through targeted mutations of its A/B domain. PLoS ONE, 1:e82.
38. Chen YL, Law PY, Loh HH. 2005. Inhibition of P13K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents, 5:575-89.
39. Chow LWC, Yiu CCP, Yip AYS, et al. 2006. The future perspectives of breast cancer therapy. Biomed Pharmacother, 60:259-62.
40. Christensen LA, Finch RA, Booker AJ, et al. 2006. Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res, 66:4089-94.
41. Chung JH, Ostrowski MC, Romigh T, et al. 2006. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet, 15:2553-9.
42. Clark GJ, Der CJ. 1995. Aberrant function of the Ras signal transduc- tion pathway in human breast cancer. Breast Cancer Res Treat, 35:133-44.
43. Clarke MF, Dick JE, Dirks PB, et al. 2006. Cancer stem cells - perspective on current status and future directions: AARC workshop on cancer stem cells. Cancer Res, 66:9339-44.
44. Claudio PP, Tonini T, Giordano A. 2002. The retinoblastoma family: twins or distant cousins? Genome Biol, 3:1-9.
45. Collins I, Garrett MD. 2005. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol, 5:366-73.
46. Comoglio PM, Trusolino L. 2005. Cancer: the matrix ix now in control. Nat Med, 11:1556-9.
47. Cox MC, Dan TD, Swain SM. 2006. Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerging Drugs, 11:489-501.
48. Cullen R, Maguire TM, McDermott EW, et al. 2001. Studies on oestrogen receptor-alpha and -beta mRNA during in breast cancer. Eur J Cancer, 37:1118-22.
49. Cuzick J, Powles T, Veronesi U, et al. 2003. Overview of the main outcomes in breast-cancer prevention. Lancet, 361:296-300.
50. Dang CV, O'Donnell KA, Zeller KI, et al. 2006. The c-Myc target gene network. Semin Cancer Biol, 16:253-64.
51. D'Cruz CM, Gunther EJ, Boxer RB, et al. 2001. C-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med, 7:235-9.
52. Dean M. 2006. Cancer stem cells: redefining the paradigm of cancer strate- gies. Mol Interv, 6:141-9.
53. deGraffenried LA, Fulcher L, Friedrichs WE, et al. 2004. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol, 15:1510-6.
54. Deng CX. 2006. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res, 34:1416-26.
55. Dick JE. 2003. Breast cancer stem cells revealed. Proc Natl Acad Sci USA, 100:3547-9.
56. Cristofano AD, Pandolfi PP. 2000. The multiple roles of PTEN in tumor suppression. Cell, 100:387-90.
57. Du W, Pogoriler J. 2006. Retinoblastoma family genes. Oncogene, 25:5190-200.
58. Dyson N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev, 12:2245-62.
59. Eckert LB, Repasky GA, Ülkü AS, et al. 2004. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res, 64:4585-92.
60. Edler L, Kopp-Schneider A. 2005. Origins of the mutational origin of cancer. Int J Epidemiol, 34:1168-70.
61. Ellard S, Gelmon KA, Chia S, et al. 2007. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. J Clin Oncol, 25 (abst 3513).
62. Elmore JG, Armstrong K, Lehman CD, et al. 2007. Screening for breast cancer. JAMA, 293:1245-56.
63. Erickson AC, Barcellos-Hoff MH. 2003. The not-so innocent bystander: the microenvironment as a therapeutic target in cancer. Expert Opin Ther Targets, 7:71-88.
64. Espinosa E, Redondo A, Vara JÁF, et al. 2006. High-throughput techniques in breast cancer: a clinical perspective. Eur J Cancer, 42:598-607.
65. Farmer H, McCabe N, Lord CJ, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434:917-21.
66. Field JK, Spandidos DA. 1990. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. Anticancer Res, 10:1-22.
67. Foster JS, Henley DC, Ahamed S, et al. 2001. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab, 12:320-7.
68. Frasor J, Danes JM, Komm B, et al. 2003. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER)α activity by ERβ in the uterus. Endocrinology, 144:4562-74.
69. Fu M, Wang C, Li Z, et al. 2004. Cyclin D1: normal and abnormal functions. Endocrinology, 145:5439-47.
70. Gaffey MJ, Frierson HFJ, Williams ME. 1993. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Mod Pathol, 6:654-9.
71. Gao X, Liu F. 2007. New agents in development of breast cancer. Curr Opin Obstet Gynecol, 19:68-74.
72. Garcia JM, Silva JM, Dominguez G, et al. 1999. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat, 57:237-43.
73. Garrett C. 2005. Targeted therapy: the fast pace of progress. Cancer Control, 12:71-2.
74. Gasco M, Shami S, Crook T. 2002. The p53 pathway in breast cancer. Breast Cancer Res, 4:70-6.
75. Gasparini G, Longo R, Torino F, et al. 2005. Therapy of breast cancer with molecular targeting agents. Ann Oncol, 16(Suppl 4):iv28-36.
76. Geyer CE, Foster J, Lindquist D, et al. 2006. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355:2733-43.
77. Giehl K. 2005. Oncogenic Ras in tumor progression and metastasis. Biol Chem, 386:193-205.
78. Granville CA, Memmott RM, Gills JJ, et al. 2006. Handikapping the race to develop inhibitors of the phosphoinoside 3-kinase/Akt/mammailian target of rapamycin pathway. Clin Cancer Res, 12:679-89.
79. Goswami A, Ranganathan P, Rangnekar VM. 2006. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer selective therapeutic agent. Cancer Res, 66:2889-92.
80. Gudmundsdottir K, Ashworth A. 2006. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene, 25:5864-74.
81. Guerin DA, Sabatini DM. 2005. An expanding role for mTOR in cancer. TRENDS Mol Med, 11:353-61.
82. Guerin M, Barrois M, Terrier MJ, et al. 1988. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res, 3:21-31.
83. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell, 100:57-70.
84. Hancock JF. 2003. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol, 4:373-84.
85. Harris H. 2005. A long view of fashions in cancer research. Bioessays, 27:833-8.
86. Harris RC, Chung E, Coffey RJ. 2003. EGF receptor ligands. Exp Cell Res, 284:2-13.
87. Harwell RM, Mull BB, Porter DC, et al. 2004. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem, 279:12695-705.
88. Haupt Y. 2004. p53 regulation: a family affair. Cell Cycle, 3:884-5.
89. Hayashi SI, Eguchi H, Tanimoto K, et al. 2003. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer, 10:193-202.
90. Head J, Johnston SRD. 2004. New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res, 6:262-8.
91. Henriksson M, Luscher B. 1996. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res, 68:109-82.
92. Herynk MH, Fuqua SAW. 2004. Estrogen receptor mutations in human disease. Endocr Rev, 25:869-98.
93. Hewitt SC, Harrell JC, Korach KS. 2005. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol, 67:285-308.
94. Hill RP. 2006. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res, 66:1891-6.
95. Hobday TJ, Perez EA. 2005. Molecularly targeted therapies for breast cancer. Cancer Control, 12:73-81.
96. Holbro T, Civenni G, Hynes NE. 2003. The erbB receptors and their role in cancer progression. Exp Cell Res, 284:99-110.
97. Hollestelle A, Elstrodt F, Nagel JHA, et al. 2007. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res, 5:195-201.
98. Huang J, Ki X, Hilf R, et al. 2005. Molecular basis of therapeutic strate- gies for breast cancer. Curr Drug Targets Immune Endocr Metabol Disord, 5:379-96.
99. Hudis CA. 2007. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med, 357:39-51.
100. Hunt KK, Keyomarsi K. 2005. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol, 15:319-26.
101. Husain HEG, Venkatraman ES, Spriggs DR. 1998. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichlo- roplatinum (II). Cancer Res, 58:1120-3.
102. Ideka K, Inoue S. 2004. Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol, 67:435-43.
103. Ingvarsson S. 2004. Genetics of breast cancer. Drugs Today, 40:991-1002.
104. Israels ED, Israels LG. 2000. The cell cycle. Oncologist, 5:510-3.
105. Jamerson MH, Johnson MD, Dickson RB. 2004. Of mice and myc: c-myc and mammary tumorigenesis. J Mammary Gland Biol Neoplasia, 9:27-37.
106. Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA Cancer J Clin, 57:43-66.
107. Johnson ML, Seidman AD. 2005. Emerging targeted therapies for breast cancer. Oncology, 19:611-8.
108. Johnson DG, Walker CL. 1999. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol, 39:295-312.
109. Johnston SRD, Hickish T, Ellis P, et al. 2003. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol, 21:2492-9.
110. Jordan VC. 2007. SERMs: meeting the promise of multifunctional medicines. JNCI, 99:350-6.
111. Jordan VC, Brodie AM. 2007. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 72:7-25.
112. Jorissen RN, Walker F, Pouliot N, et al. 2003. Epidermal growth fac- tor receptor:mechanisms of activation and signalling. Exp Cell Res, 284:31-53.
113. Kaklamani V, O'Regan RM. 2004. New targeted therapies in breast cancer. Semin Oncol, 31(Suppl 4):20-5.
114. Kaptain S, Tan LK, Chen B. 2001. Her-2/neu and breast cancer. Diagn Mol Pathol, 10:139-52.
115. Kauff ND, Barakat RR. 2007. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA 2. J Clin Oncol, 25:2921-7.
116. Kelland L. 2007. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7:573-84.
117. Kenemans R, Verstraeten RA, Verheijen RHM. 2004. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas, 49:34-43.
118. Kerlikowske K, Grady D, Barclay J, et al. 1996. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA, 276:33-8.
119. Khan S, Kumagai T, Vora J, et al. 2004. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer, 112:407-10.
120. Kim D, Cheng GZ, Lindsley CW, et al. 2005. Targeting the phosphatidylinositol-3-kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs, 6:1250-8.
121. Kim RH, Mak TW. 2006. Tumours and tremors: how PTEN regulation underlies both. Br J Cancer, 94:620-4.
122. Kinzler KW, Vogelstein B. 1997. Gatekeepers and caretakers. Nature, 386:761-2.
123. Kinzler KW, Vogelstein B. 1998. Landscaping the cancer terrain. Science, 280:1036-7.
124. Klapper LN, Kirschbaum MH, Sela M, et al. 2000. Biochemical and clini- cal implications of the erbB/HER signaling network of growth factor receptors. Adv Cancer Res, 77:25-79.
125. Knudsen ES, Knudsen KE. 2006. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med, 231:1271-81.
126. Knudson AG Jr. 1971. Mutation and cancer: statistical study of retinoblasatoma. Proc Natl Acad Sci USA, 68:820-3.
127. Konecny GE, Pegram MD, Venkatesan N, et al. 2006. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-over-expression and trastuzumab-treated breast cancer cells. Cancer Res, 66:1630-9.
128. Kuiper GG, Enmark E, Pelto-Huikko M, et al. 1996. Cloning of novel receptor expressed in rat prostrate and ovary. Proc Natl Acad Sci USA, 93:5925-30.
129. Lacroix M, Toillon RA, Leclercq G. 2006. p53 and breast cancer: an update. Endocr Relat Cancer, 13:293-325.
130. Lane DP. 1992. p53: the guardian of the genome. Nature, 358:15-6.
131. Lebowitz PF, Eng-Wong J, Widemann BC, et al. 2005. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res, 11:1247-52.
132. Li J, Yen C, Liaw D, et al. 1997. PTEN, a putative protein tyrosine phos- phatase gene mutated in human brain, breast, and prostate cancer. Science, 275:1943-7.
133. Liao DJ, Dickson RB. 2000. c-Myc in breast cancer. Endocr Relat Cancer, 7:143-64.
134. Liaw D, Marsh DJ, Li J, et al. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet, 16:64-7.
135. Liotta LA, Kohn EC. 2001. The microenvironment of the tumor-host inter- face. Nature, 411:375-9.
136. Liu TG, Yin JQ, Shang BY, et al. 2004. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther, 11:748-56.
137. Lodén M, Stoghall M, Nielsen NH, et al. 2002. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene, 21:4680-90.
138. Lønning PE, Sørlie T, Børresen-Dale AL, et al. 2005. Genomics in breast cancer - therapeutic implications. Nat Clin Prac Oncol, 2:26-33.
139. Lu Y, Lin YZ, LaPushin R, et al. 1999. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene, 18:7034-45.
140. Lu Y, Wang H, Mills GB. 2003. Targeting the P13K-AKT pathway for cancer therapy. Rev Clin Exp Hematol, 7:205-28.
141. Lynch HT, Lynch JF, Rubinstein WS. 2001. Prophylactic mastectomy: obstacles and benefits. J Natl Cancer Inst, 93:1586-7.
142. Macdonald F, Ford CHJ, Casson AG. 2004. Molecular biology of cancer. 2nd ed. London: BIOS Scientific.
143. Macleod K. 2000. Tumor suppressor genes. Curr Opin Genet Dev, 10:81-93.
144. Maehama T, Dixon JE. 1999. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol, 9:125-8.
145. Magnifico A, Albano L, Campaner S, et al. 2007. Protein kinase Cα determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res, 67:5308-17.
146. Malumbres M. 2005. Revisiting the "cdk-centric" view of the mammalian cell cycle. Cell Cycle, 4:206-10.
147. Marcum JA. 2002. The transformation of oncology in the twentieth century: the molecularization of cancer. In: Burns CR, O'Neill YV, Albou P, et al eds. Proceedings of the 37th International Congress on the History of Medicine. Galveston, TX: University of Texas Medical Branch. p 41-9.
148. Marcus AI, Zhou J, O'Brate A, et al. 2005. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res, 65:3883-93.
149. Margolin S, Lindblom A. 2006. Familial breast cancer, underlying genes, and clinical implications: a review. Crit Rev Oncog, 12:75-113.
150. Marsh DJ, Coulon V, Lunetta KL, et al. 1998. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet, 7:507-15.
151. Marsh S, McLeod HI. 2007. Pharmacogenetics and oncology for breast cancer. Expert Opin Pharmacother, 8:119-27.
152. Massard C, Deutsch E, Soria J-C. 2006. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol, 17:1620-4.
153. Meric-Bernstam F, Hung MC. 2006. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res, 12:6326-30.
154. Messinis IE. 2006. From menarche to regular menstruation: endocrinological background. Ann N Y Acad Sci, 1092:49-56.
155. Michels KB, Mohllajee AP, Roset-Bahmanyar E, et al. 2007. Diet and breast cancer: a review of the prospective observational studies. Cancer, 109:2712-49.
156. Morgan DO. 1997. Cyclin-dependent kinases: engines, clocks, and micro- processors. Annu Rev Cell Dev Biol, 13:261-91.
157. Möröy T, Geisen C. 2004. Cyclin E. Int J Biochem Cell Biol, 36:1424-39.
158. Morris EJ, Dyson NJ. 2001. Retinoblastoma protein partners. Adv Cancer Res, 82:1-54.
159. Motoyama N, Naka K. 2004. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev, 14:11-6.
160. Mouridesen H, Gershanovich M, Sun Y, et al. 2003. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol, 21:2101-9.
161. Moy B, Goss PE. 2006. Lapatinib: current status and future directions in breast cancer. Oncologist, 11:1047-57.
162. Murray AW. 2004. Recycling the cell cycle: cyclins revisited. Cell, 116:221-34.
163. Muss HB. 2006. Targeted therapies for metastatic breast cancer. N Engl J Med, 355:2783-5.
164. Nagata Y, Lan KH, Zhou X, et al. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6:117-27.
165. Nahta R, Esteva FJ. 2007. Trastuzumab: triumphs and tribulations. Onco- gene, 26:3637-43.
166. Nass SJ, Dickson RB. 1997. Defining a role for c-Myc in breast tumorigen- esis. Breast Cancer Res Treat, 44:1-22.
167. Nathanson KL, Wooster R, Weber BL. 2001. Breast cancer genetics: what we know and what we need. Nat Med, 7:552-6.
168. Oesterreich S, Fuqua SAW. 1999. Tumor suppressor genes in breast cancer. Endocr Relat Cancer, 6:405-19.
169. Oliveira AM, Ross JS, Fletcher JA. 2005. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol, 124(Suppl 1):S16-28.
170. O'Regan RM, Khuri FR. 2004. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? Endocr Relat Cancer, 11:191-205.
171. O'Regan RM. 2006. Chemoprevention of breast cancer. Lancet, 367:1382-3.
172. Osborne C, Wilson P, Tripathy D. 2004. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist, 9:361-77.
173. Oster SK, Ho CSW, Soucie EL, et al. 2002. The myc oncogene: MarvouslY Complex. Adv Cancer Res, 84:81-154.
174. Panigrahi AR, Pinder SE, Chan SY, et al. 2004. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol, 204:93-100.
175. Park MT, Lee SJ. 2003. Cell cycle and cancer. J Biochem Mol Biol, 36:60-5.
176. Pavelić K, Gall-Trošelj K. 2001. Recent advances in molecular genetics of breast cancer. J Mol Med, 79:566-73.
177. Pegram MD, Pietras R, Bajamonde A, et al. 2005. Targeted therapy: wave if the future. J Clin Oncol, 23:1776-81.
178. Pelengaris S, Khan M. 2003. The many faces of c-MYC. Arch Biochem Biophys, 416:129-36.
179. Perou CM, Sørlie T, Elsen MB, et al. 2000. Molecular portraits of human breast tumors. Nature, 406:747-52.
180. Petrocelli T, Slingerland JM. 2001. PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res, 3:356-60.
181. Piccart-Gebhart MJ. 2006. Adjuvant trastuzumab therapy for HER2-overex- pressing breast cancer: what we know and what we still need to learn. Eur J Cancer, 42:1715-9.
182. Pierce JP, Natarajan L, Caan BJ, et al. 2007. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA, 298:289-98.
183. Ponti D, Costa A, Zaffaroni N, et al. 2005. In vitro propagation of breast tumorigenic cancer cells with stem/progenitor cell properties. Cancer Res, 65:5506-11.
184. Ponti D, Zaffaroni N, Capelli C, et al. 2005. Breast cancer cells: an overview. Eur J Cancer, 42:1219-24.
185. Pruthi S, Brandt KR, Degnim AC, et al. 2007. A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc, 82:999-1012.
186. Rebbeck TR, Friebel T, Lynch HT, et al. 2004. Bilateral prophylactic mas- tectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol, 22:1055-62.
187. Rhei E, Kang L, Bogomolniy F, et al. 1997. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res, 57:3657-9.
188. Robson M, Offit K. 2007. Management of an inherited predisposition to breast cancer. N Eng J Med, 357:154-62.
189. Rochefort H, Glondu M, Sahla ME, et al. 2003. How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer, 10:261-6.
190. Rosen EM, Fan S, Pestell RG, et al. 2003. BRCA1 gene in breast cancer. J Cell Physiol, 196:19-41.
191. Ross JS, Fletcher JA. 1998. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells, 16:413-28.
192. Ross JS, Fletcher JA, Linette GP, et al. 2003. The HER-2/neu gene and protein in breast cancer 2003: biomarkers and target of therapy. Oncologist, 8:307-25.
193. Ross JS, Fletcher JA, Bloom KJ, et al. 2004a. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3:379-98.
194. Ross JS, Linette GP, Stec J, et al. 2004b. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn, 4:169-88.
195. Roy PG, Thompson AM. 2006. Cyclin D1 and breast cancer. Breast, 15:718-27.
196. Russo J, Russo IH. 2006. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol, 102:89-96.
197. Ryan KM, Birnie GD. 1996. Myc oncogenes: the enigmatic family. Biochem J, 314:713-21.
198. Sánchez I, Dynlacht BD. 2005. New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol, 16:311-21.
199. Sandal T. 2002. Molecular aspects of the mammalian cell cycle and cancer. Oncologist, 7:73-81.
200. Schafer KA. 1998. The cell cycle: a review. Vet Pathol, 35:461-78.
201. Scheuer L, Kauff N, Robson M, et al. 2002. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol, 20:1260-8.
202. Schulz WA. 2006. Molecular biology of human cancers. an advanced student's textbook. Dordrecht: Springer.
203. Seeger H, Wallwiener D, Mueck AO. 2003. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes, 111:47-8.
204. Segota E, Bukowski RM. 2004. The promise of targeted therapy: cancer drugs become more specific. Cleve Clin J Med, 71:551-60.
205. Senderowicz AM. 2003. Small-molecular cyclin-dependent kinase modula- tors. Oncogene, 22:6609-20.
206. Seynaeve C, Verweij J. 2004. Targeted therapy: ready for prime time? Cancer Treat Res, 120:1-15.
207. Sharkey RM, Goldenberg DM. 2006. Targeted therapy of cancer: new prospects of antibodies and immunoconjugates. CA Cancer J Clin, 56:226-43.
208. Sherr CJ. 1996. Cancer cell cycles. Science, 274:1672-7.
209. Sherr CJ. 2000. Cancer cell cycle revisited. Cancer Res, 60:3689-95.
210. Sherr CJ. 2004. Principles of tumor suppression. Cell, 116:235-46.
211. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 13:1501-12.
212. Sherr CJ, Roberts JM. 2004. Living with and without cyclins and cyclin- dependent kinases. Genes Dev, 18:2699-711.
213. Shin I, Kim S, Song H, et al. 2005. H-Ras-specific activation of Rac- MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem, 280:14675-83.
214. Simin K, Wu H, Lu L, et al. 2004. pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. PLoS Biol, 2:194-205.
215. Simpson L, Parsons R. 2001. PTEN: life as a tumor suppressor. Exp Cell Res, 264:29-41.
216. Sledge GW Jr. 2001. Breast cancer in the clinic: treatments past, treatments future. J Mammary Gland Biol Neoplasia, 6:487-95.
217. Sledge GW Jr. 2005. What is targeted therapy? J Clin Oncol, 23:1614-5.
218. Sledge GW Jr, Miller KD. 2003. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer, 39:1668-75.
219. Soos TJ, Park M, Kiyokawa H, et al. 1998. Regulation of the cell cycle by CDK inhibitors. Results Probl Cell Differ, 22:111-31.
220. Stevenson LE, Ravichandran KS, Frackelton AR Jr. 1999. Shc dominant negative disrupts cell cycle progression in both G0-G1 and G2-M of ErbB2-positive breast cancer cells. Cell Growth Differ, 10:61-71.
221. Stoff-Khalili MA, Dall P, Curiel DT. 2006. Gene therapy for carcinoma of the breast. Cancer Gene Ther, 13:633-47.
222. Sui G, Soohoo C, Affar EB, et al. 2002. A DNA vector-based RNAi technol- ogy to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA, 99:5515-20.
223. Sunpaweravong S, Sunpaweravong P. 2005. Recent developments in critical genes in the molecular biology of breast cancer. Asian J Surg, 28:71-5.
224. Sutherland RL, Musgrove EA. 2004. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia, 9:95-104.
225. Takimoto R, Wang W, Dicker DT, et al. 2002. The mutant p53-confor- mation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther, 1:47-55.
226. Tamura M, Gu J, Tran H, et al. 1999. PTEN gene and integrin signaling in cancer. J Natl Cancer Inst, 1:1820-8.
227. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: in vitro hypothesis, in vivo veritas. Nat Rev, 6:909-23.
228. Tovey SM, Reeves JR, Stanton P, et al. 2006. Low expression of HER2 pro- tein in breast cancer is biologically significant. J Pathol, 210:358-62.
229. Tripathy D. 2005. Targeted therapies in breast cancer. Breast J, 11(Suppl 1): S30-5.
230. Tsang CK, Qi H, Liu LF, et al. 2007. Targeting mammalian target of rapamy- cin (mTOR) for health and disease. Drug Discov Today, 12:112-24.
231. Turner N, Tutt A, Ashworth A. 2005. Targeting the DNA repair defect in BRCA tumours. Curr Opin Pharmacol, 5:388-93.
232. Tyson JJ, Csikasz-Nagy A, Novak B. 2002. The dynamics of cell cycle regulation. BioEssays, 24:1095-1109.
233. Varmus H, Weinberg RA. 1993. Genes and the biology of cancer. New York: Scientific American Library.
234. Venkitaraman AR. 2002. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108:171-82.
235. Vermeulen K, van Bockstaele DR, Berneman ZN. 2003. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif, 36:131-49.
236. Vignot S, Faivre S, Aguirre D, et al. 2005. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol, 16:525-37.
237. Vogel VG. 2007. Chemoprevention strategies 2006. Curr Treat Options Oncol, 8:74-88.
238. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med, 10:789-99.
239. von Lintig FC, Dreilinger AD, Varki NM, et al. 2000. Ras activation in human breast cancer. Breast Cancer Res Treat, 62:51-62.
240. Waite KA, Eng C. 2002. Protean PTEN: form and function. Am J Hum Genet, 70:829-44.
241. Walsh T, King MC. 2007. Ten genes for inherited breast cancer. Cancer Cell, 11:103-5.
242. Walshe JM, Denduluri N, Berman AW, et al. 2006. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer, 6:535-9.
243. Wang W, Rastinejad F, El-Deiry WS. 2003. Restoring p53-dependent tumor suppression. Cancer Biol Ther, 2(Suppl 1):S55-63.
244. Wang Y, Liu S, Zhang G, et al. 2005. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res, 7:R220-8.
245. Wärnberg F, White D, Anderson E, et al. 2006. Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res, 8(2):R21-30.
246. Watson PH, Pon RT, Shiu RPC. 1991. Inhibition of c-myc expression by phophorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res, 51:3996-4000.
247. Weinberg RA. 1998. One renegade cell: how cancer begins. New York: Basic Books.
248. Weng LP, Smith WM, Dahia PLM, et al. 1999. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res, 59:5808-14.
249. Wesierska-Gadek J, Gueorguieva M, Horky M. 2003. Dual action of cyclin- dependent kinase inhibitors: induction of cell cycle arrest and apoptosis: a comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol, 55:895-902.
250. Whyte P. 1995. The retinoblastoma protein and its relatives. Semin Cancer Biol, 6:83-90.
251. Wicha MS, Liu S, Dontu G. 2006. Cancer stem cells: an old idea - a para- digm shift. Cancer Res, 66:1883-90.
252. Wiseman BS, Werb Z. 2002. Stromal effects on mammary gland develop- ment and breast cancer. Science, 296:1046-9.
253. Witton CJ, Reeves JR, Going JJ, et al. 2003. Expression of the HER1-4 fam- ily of receptor tyrosine kinases in breast cancer. J Pathol, 200:290-7.
254. Wren BG. 2004. Do female sex hormones initiate breast cancer? A review of the evidence. Climacteric, 7:120-8.
255. Wunderlich V. 2006. Early references to the mutational origin of cancer. Int J Epidemiol, 14:1-2.
256. Yang DC, Elliot RL, Head JF. 2002. Gene targets of antisense therapies in breast cancer. Expert Opin Ther Targets, 6:375-85.
257. Yang SP, Song ST, Song HF. 2003. Advancements of antisense oligonucle- otides in treatment of breast cancer. Acta Pharmacol Sin, 24:289-95.
258. Yarden RI, Papa MZ. 2006. BRCA1 at the crossroads of multiple cellular pathways: approaches for therapeutic interventions. Mol Cancer Ther, 5:1396-404.
259. Zakaria S, Degnim AC. 2007. Prophylactic mastectomy. Surg Clin North Am, 87:317-31.
260. Zheng L, Lee WH. 2001. The retinoblastoma gene: a prototypic and mul- tifunctional tumor suppressor. Exp Cell Res, 264:2-18.